LAUSR

Neoadjuvant Therapy Neoadjuvant therapy refers to any treatment that is given for cancer before surgery, with the goal of making the surgery more likely to be successful and improve the chance of long-term survival. The most common setting for neoadjuvant therapy is when a patient with early-stage lung cancer receives systemic therapy prior to surgery with any of the following: • Chemotherapy, often given for 3 to 4 months • Immunotherapy, for 2 months (as currently approved) The benefit of neoadjuvant therapy is that it provides treatment at the earliest opportunity, enables completion of therapy quickly, potentially leads to a less extensive surgery being required, and allows for measurement of systemic therapy effect on visible disease, which is correlated with long-term outcomes.